Histone Methyltransferases Regulate the Transcriptional Expression of ERα and the Proliferation of Tamoxifen-resistant Breast Cancer Cells

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2020 Jan 4

PMID 31897900

Citations 16

Authors

Seung-Su Kim

Min-Ho Lee

Mi-Ock Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: Although tamoxifen remains the frontline treatment for ERα-positive breast cancers, resistance to this drug limits its clinical efficacy. Most tamoxifen-resistant patients retain ERα expression which may support growth and progression of breast cancers. Therefore, we investigated epigenetic regulation of ERα that may provide a rationale for targeting ERα in these patients.

Methods: Expression levels of the mixed-lineage leukemia (MLL) family of proteins in tamoxifen-resistant breast cancer cells and publicly available breast cancer patient data sets were analyzed. Histone methylation levels in ERα promoter regions were assessed using chromatin immunoprecipitation. Expression levels of ERα and its target gene were analyzed using western blotting and real-time qPCR. Cell-cycle was analyzed by flow cytometry.

Results: The expression of MLL3 and SET-domain-containing 1A (SET1A) were increased in tamoxifen-resistant breast cancers. An MLL3 chromatin immunoprecipitation-sequencing data analysis and chromatin immunoprecipitation experiments for MLL3 and SET1A suggested that these proteins bound to enhancer or intron regions of the ESR1 gene and regulated histone H3K4 methylation status. Depletion of MLL3 or SET1A downregulated the expression level of ERα and inhibited the growth of tamoxifen-resistant breast cancer cells. Additional treatment with fulvestrant resulted in a synergistic reduction of ERα levels and the growth of the cells.

Conclusions: The enhanced expression of MLL3 and SET1A in tamoxifen-resistant breast cancer cells supported the ERα-dependent growth of these cells by increasing ERα expression. Our results suggest that targeting these histone methyltransferases might provide an attractive strategy to overcome endocrine resistance.

Citing Articles

Secreted LGALS3BP facilitates distant metastasis of breast cancer.

Kim S, Park I, Kim J, Ka N, Lim G, Park M Breast Cancer Res. 2025; 27(1):4.

PMID: 39789641 PMC: 11715970. DOI: 10.1186/s13058-024-01958-8.

Crosstalk of methylation and tamoxifen in breast cancer (Review).

Shen J, He Y, Li S, Chen H Mol Med Rep. 2024; 30(4).

PMID: 39129315 PMC: 11338244. DOI: 10.3892/mmr.2024.13304.

Stilbenes: a promising small molecule modulator for epigenetic regulation in human diseases.

Tian J, Jin L, Liu H, Hua Z Front Pharmacol. 2023; 14:1326682.

PMID: 38155902 PMC: 10754530. DOI: 10.3389/fphar.2023.1326682.

WDR82-Mediated H3K4me3 Is Associated with Tumor Proliferation and Therapeutic Efficacy in Pediatric High-Grade Gliomas.

Wadhwani N, Nayak S, Wang Y, Hashizume R, Jie C, Mania-Farnell B Cancers (Basel). 2023; 15(13).

PMID: 37444539 PMC: 10340597. DOI: 10.3390/cancers15133429.

The Role of Histone Modification in DNA Replication-Coupled Nucleosome Assembly and Cancer.

Zhang Y, Zhang Q, Zhang Y, Han J Int J Mol Sci. 2023; 24(5).

PMID: 36902370 PMC: 10003558. DOI: 10.3390/ijms24054939.

References

Liu L, Kimball S, Liu H, Holowatyj A, Yang Z . Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget. 2014; 6(4):2466-82. PMC: 4385864. DOI: 10.18632/oncotarget.2967. View

Miller L, Smeds J, George J, Vega V, Vergara L, Ploner A . An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005; 102(38):13550-5. PMC: 1197273. DOI: 10.1073/pnas.0506230102. View

Osborne C, Wakeling A, Nicholson R . Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004; 90 Suppl 1:S2-6. PMC: 2750773. DOI: 10.1038/sj.bjc.6601629. View

Feng Q, Zhang Z, Shea M, Creighton C, Coarfa C, Hilsenbeck S . An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014; 24(7):809-19. PMC: 4085766. DOI: 10.1038/cr.2014.71. View

Robinson J, Thorvaldsdottir H, Winckler W, Guttman M, Lander E, Getz G . Integrative genomics viewer. Nat Biotechnol. 2011; 29(1):24-6. PMC: 3346182. DOI: 10.1038/nbt.1754. View

Thrane S, Lykkesfeldt A, Larsen M, Sorensen B, Yde C . Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat. 2013; 139(1):71-80. DOI: 10.1007/s10549-013-2485-2. View

Higuchi T, Gohno T, Nagatomo T, Tokiniwa H, Niwa T, Horiguchi J . Variation in use of estrogen receptor-α gene promoters in breast cancer compared by quantification of promoter-specific messenger RNA. Clin Breast Cancer. 2013; 14(4):249-57. DOI: 10.1016/j.clbc.2013.10.015. View

Nass N, Kalinski T . Tamoxifen resistance: from cell culture experiments towards novel biomarkers. Pathol Res Pract. 2015; 211(3):189-97. DOI: 10.1016/j.prp.2015.01.004. View

Kang H, Lee M, Kang H, Kim S, Ahn J, Na H . Differential regulation of estrogen receptor α expression in breast cancer cells by metastasis-associated protein 1. Cancer Res. 2014; 74(5):1484-94. DOI: 10.1158/0008-5472.CAN-13-2020. View

10.

Salz T, Deng C, Pampo C, Siemann D, Qiu Y, Brown K . Histone Methyltransferase hSETD1A Is a Novel Regulator of Metastasis in Breast Cancer. Mol Cancer Res. 2014; 13(3):461-9. DOI: 10.1158/1541-7786.MCR-14-0389. View

11.

Kuske B, Naughton C, Moore K, Macleod K, Miller W, Clarke R . Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Endocr Relat Cancer. 2006; 13(4):1121-33. DOI: 10.1677/erc.1.01257. View

12.

Jeong K, Kim K, Situ A, Ulmer T, An W, Stallcup M . Recognition of enhancer element-specific histone methylation by TIP60 in transcriptional activation. Nat Struct Mol Biol. 2011; 18(12):1358-65. PMC: 3230772. DOI: 10.1038/nsmb.2153. View

13.

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

14.

Lumachi F, Brunello A, Maruzzo M, Basso U, Basso S . Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013; 20(5):596-604. DOI: 10.2174/092986713804999303. View

15.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X . Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016; 534(7605):47-54. PMC: 4910866. DOI: 10.1038/nature17676. View

16.

Tajima K, Yae T, Javaid S, Tam O, Comaills V, Morris R . SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes. Nat Commun. 2015; 6:8257. PMC: 4667427. DOI: 10.1038/ncomms9257. View

17.

Rao R, Dou Y . Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. 2015; 15(6):334-46. PMC: 4493861. DOI: 10.1038/nrc3929. View

18.

Torre L, Islami F, Siegel R, Ward E, Jemal A . Global Cancer in Women: Burden and Trends. Cancer Epidemiol Biomarkers Prev. 2017; 26(4):444-457. DOI: 10.1158/1055-9965.EPI-16-0858. View

19.

Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G . A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res. 2008; 14(6):1744-52. PMC: 2912334. DOI: 10.1158/1078-0432.CCR-07-1833. View

20.

Yu L, Liang Y, Cao X, Wang X, Gao H, Lin S . Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer. Oncogene. 2016; 36(20):2910-2918. PMC: 5436938. DOI: 10.1038/onc.2016.433. View